Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 53, Issue 7, Pages 2913-2926Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm901888x
Keywords
-
Categories
Funding
- Australian Research Council [DP0877554]
- Eskitis Institute for Cell and Molecular Therapies
- EU
- Australian Research Council [DP0877554] Funding Source: Australian Research Council
Ask authors/readers for more resources
The contribution of membrane-bound carbonic anhydrases (CAs) to hypoxic tumor growth and progression in cancer implicates cancer-associated CAs as a promising drug target for oncology. In this paper, we present a new class of sulfonamide-linked neoglycoconjugate that was designed to selectively target and inhibit the extracellular domains of the cancer-relevant CA isozymes. We describe the application of novel, yet straightforward, chemistry toward the synthesis of inhibitors that comprise both S-glycosyl sulfenamides and S-glycosyl sulfonamides. We also present the CA inhibition profile of our new neoglycoconjugates, more specifically a library of 30 compounds (3-32) that were designed to optimize both SAR (structure activity relationship) and SPR (structure property relationship) characteristics. We show that our approach produces neutral, water-soluble, and potent inhibitors (K(i)s in the low nanomolar range) that target cancer-associated CAs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available